Long-term outcomes of catheter ablation in atrial fibrillation patients: the impact of changed CHA2DS2-VASc scores

Introduction Catheter ablation is widely utilized for atrial fibrillation (AF) management, yet long-term recurrence remains challenging. It is critical to understand how cardiovascular comorbidities, as captured by the CHA 2 DS 2 -VASc score, affect AF recurrence and major adverse cardiovascular and cerebrovascular events (MACCE) after ablation. Methods This analysis used data from a prospectively maintained, single-center observational registry (ChiCTR-OCH-14004674) involving 1,685 patients who underwent AF catheter ablation between January 2015 and December 2019. The relationship between longitudinal (time-updated) CHA 2 DS 2 -VASc score changes and AF recurrence and MACCE was examined with time-to-event methods. Results Over the course of a 58.1 ± 17.1-month follow-up period, the CHA 2 DS 2 -VASc score rose from 1.84 ± 1.35 to 3.10 ± 1.44. AF recurrence was observed in 442 patients (26.2%). Patients with a changed CHA 2 DS 2 -VASc score demonstrated a higher incidence of AF recurrence (hazard ratio [HR] and 95% Confidence Interval [CI]: 1.552 (1.398–1.724), p < 0.001) and MACCE post-ablation (HR [95%CI]: 4.90 (3.21–7.50)). In a time-updated Cox model that used only information available before each event, this association persisted (AF recurrence HR [95% CI]: HR 4.98 (3.87–6.40) unadjusted; 5.48 (4.22–7.10) adjusted for age, sex and baseline CHA₂DS₂-VASc). Multivariable analyses identified an increasing CHA 2 DS 2 -VASc score, along with new-onset comorbidities such as diabetes, hypertension, and vascular disease, as significant predictors of AF recurrence. An increased CHA 2 DS 2 -VASc score was also markedly associated with the elevated MACCE risk. Notably, crossing an age threshold itself was not independently associated with recurrence; the prognostic signal was carried by incident non-age comorbidities rather than by aging per se. Discussion A changed CHA 2 DS 2 -VASc score serves as a dynamic and salient marker for AF recurrence and MACCE following AF ablation. Our findings highlight the importance of vigilant monitoring and management of cardiovascular risk factors in post-ablation patients.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fcvm.2026.1949346
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term outcomes of catheter ablation in atrial fibrillation patients: the impact of changed CHA2DS2-VASc scores

Bing Rong, Kai Zhang, Mei Li, Xinyan Yang et al.
1 links
Frontiers in Cardiovascular Medicine
Atrial Fibrillation Management and Outcomes
article

Long-term outcomes of catheter ablation in atrial fibrillation patients: the impact of changed CHA2DS2-VASc scores

Bing Rong, Kai Zhang, Mei Li, Xinyan Yang, Wenqiang Han, Mingjie Lin, Jingquan Zhong, Juntao Wang, Tongshuai Chen
article en

Abstract

Introduction Catheter ablation is widely utilized for atrial fibrillation (AF) management, yet long-term recurrence remains challenging. It is critical to understand how cardiovascular comorbidities, as captured by the CHA 2 DS 2 -VASc score, affect AF recurrence and major adverse cardiovascular and cerebrovascular events (MACCE) after ablation. Methods This analysis used data from a prospectively maintained, single-center observational registry (ChiCTR-OCH-14004674) involving 1,685 patients who underwent AF catheter ablation between January 2015 and December 2019. The relationship between longitudinal (time-updated) CHA 2 DS 2 -VASc score changes and AF recurrence and MACCE was examined with time-to-event methods. Results Over the course of a 58.1 ± 17.1-month follow-up period, the CHA 2 DS 2 -VASc score rose from 1.84 ± 1.35 to 3.10 ± 1.44. AF recurrence was observed in 442 patients (26.2%). Patients with a changed CHA 2 DS 2 -VASc score demonstrated a higher incidence of AF recurrence (hazard ratio [HR] and 95% Confidence Interval [CI]: 1.552 (1.398–1.724), p < 0.001) and MACCE post-ablation (HR [95%CI]: 4.90 (3.21–7.50)). In a time-updated Cox model that used only information available before each event, this association persisted (AF recurrence HR [95% CI]: HR 4.98 (3.87–6.40) unadjusted; 5.48 (4.22–7.10) adjusted for age, sex and baseline CHA₂DS₂-VASc). Multivariable analyses identified an increasing CHA 2 DS 2 -VASc score, along with new-onset comorbidities such as diabetes, hypertension, and vascular disease, as significant predictors of AF recurrence. An increased CHA 2 DS 2 -VASc score was also markedly associated with the elevated MACCE risk. Notably, crossing an age threshold itself was not independently associated with recurrence; the prognostic signal was carried by incident non-age comorbidities rather than by aging per se. Discussion A changed CHA 2 DS 2 -VASc score serves as a dynamic and salient marker for AF recurrence and MACCE following AF ablation. Our findings highlight the importance of vigilant monitoring and management of cardiovascular risk factors in post-ablation patients.

Frontiers in Cardiovascular MedicineVol. 13
Shandong University of Traditional Chinese Medicine (CN), Shandong University (CN), Qilu Hospital of Shandong University (CN)
National Natural Science Foundation of China
Good health and well-being
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon